Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Simple Summary

Between 2002 and 2020, 31 patients with early penile cancer were treated with high-dose-rate brachytherapy (HDR-BT) at a dose of 18 × 3 Gy twice daily. The technique of the hollow steel needles fixed by the template was used. At a median follow-up of 117.5 months, the probability of local control at 5- and 10-years was 80.7% and 68.3%, respectively, with a probability of penis sparing of 80.6% and 62.1%. Cause-specific suervival was 100%. Only one case of radionecrosis was observed. These results show HDR-BT can achieve results that are comparable to low-dose rate BT while also allowing for organ preservation.

Abstract

Background: Low-dose-rate brachytherapy is an effective organ-sparing treatment for patients with early-stage penile cancer. However, only limited data are available on the role of high-dose-rate brachytherapy (HDR-BT) in this clinical setting. Methods: Between 2002 and 2020, 31 patients with early penile cancer were treated at our center with interstitial HDR BT at a dose of 18 × 3 Gy twice daily. A breast brachytherapy template was used for the fixation of stainless hollow needles. Results: The median follow-up was 117.5 months (range, 5–210). Eight patients (25.8%) developed a recurrence; of these, seven were salvaged by partial amputation. Six patients died of internal comorbidities or a second cancer. The probability of local control at 5 and 10 years was 80.7% (95% CI: 63.7–97.7%) and 68.3% (95% CI: 44.0–92.6%), respectively. Cause-specific survival was 100%. Only one case of radiation-induced necrosis was observed. The probability of penile sparing at 5 and 10 years was 80.6% (95% CI: 63.45–97.7%) and 62.1% (95% CI: 34.8–89.4%), respectively. Conclusions: These results show that HDR-BT for penile cancer can achieve results comparable to LDR-BT with organ sparing. Despite the relatively large patient cohort—the second largest reported to date in this clinical setting—prospective data from larger samples are needed to confirm the role of HDR-BT in penile cancer.

Details

Title
High-Dose-Rate Brachytherapy as an Organ-Sparing Treatment for Early Penile Cancer
Author
Pohanková, Denisa 1 ; Sirák, Igor 1   VIAFID ORCID Logo  ; Vošmik, Milan 1   VIAFID ORCID Logo  ; Kašaová, Linda 1 ; Grepl, Jakub 1   VIAFID ORCID Logo  ; Paluska, Petr 1 ; Holub, Lukáš 2 ; Špaček, Jiří 2 ; Hodek, Miroslav 1   VIAFID ORCID Logo  ; Kopeček, Martin 3 ; Petera, Jiří 1 

 Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University, Sokolská 581, 50005 Hradec Králové, Czech Republic 
 Department of Urology, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Charles University, Sokolská 581, 50005 Hradec Králové, Czech Republic 
 Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 50003 Hradec Králové, Czech Republic 
First page
6248
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2756666778
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.